C8166
|
CC50 |
|
Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31310115]
|
Caco-2
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915]
|
CCRF-CEM
|
IC50 |
> 100 μM
Compound: 3TC, Epivir
|
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
|
[PMID: 21700368]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28688280]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28094179]
|
CCRF-CEM
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
EC50 |
0.099 μM
Compound: 5, 3TC
|
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
IC50 |
50 μM
Compound: beta-L-oxathiolanecytosine(3TC)
|
Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis
Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis
|
10.1016/0960-894X(95)00343-R
|
CEM-SS
|
ED50 |
|
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
|
[PMID: 15217281]
|
CEM-SS
|
EC50 |
|
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
|
[PMID: 22858097]
|
CHO
|
IC50 |
54.2 μM
Compound: lamivudine
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503]
|
COLO 320
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis
|
[PMID: 24177359]
|
H9
|
CC50 |
> 200 μM
Compound: Lamivudine
|
Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay
Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay
|
[PMID: 34245947]
|
H9
|
EC50 |
0.06 μM
Compound: 3TC, NSC-697911, (2R-cis)-lamivudine
|
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
|
[PMID: 11430019]
|
H9
|
EC50 |
0.06 μM
Compound: 3TC, NSC-697911, (2R-cis)-lamivudine
|
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
|
[PMID: 11430019]
|
HEK293
|
EC50 |
> 300 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
CC50 |
|
Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay
Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay
|
[PMID: 32678592]
|
HEK293
|
EC50 |
|
Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay
Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay
|
[PMID: 32678592]
|
HEK293
|
EC50 |
3.25 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
3.54 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
3.9 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
4.06 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
4.24 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
4.48 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
4.68 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
4.78 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
5.43 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK293
|
EC50 |
7.16 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
|
[PMID: 20308377]
|
HEK-293T
|
CC50 |
|
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
|
[PMID: 17470654]
|
HEK-293T
|
EC50 |
|
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
|
[PMID: 22148316]
|
HeLa
|
CC50 |
> 20 μM
Compound: Lamivudine
|
Cytotoxicity against mock-infected human HeLa cells by MTT assay
Cytotoxicity against mock-infected human HeLa cells by MTT assay
|
[PMID: 25682562]
|
HeLa
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
|
[PMID: 24177359]
|
HeLa
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
|
[PMID: 24177359]
|
HeLa
|
EC50 |
> 436 μM
Compound: 3TC, Lamivudine
|
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
|
[PMID: 22352809]
|
HeLa
|
EC50 |
> 436.6 μM
Compound: 1, lamivudine, 3TC
|
Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay
Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay
|
[PMID: 22533850]
|
HeLa
|
EC50 |
11.3 μM
Compound: 3TC, Lamivudine
|
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
|
[PMID: 22352809]
|
HeLa
|
EC50 |
11.4 μM
Compound: 1, lamivudine, 3TC
|
Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
|
[PMID: 22533850]
|
HeLa
|
EC50 |
32.7 μM
Compound: 1, lamivudine, 3TC
|
Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
|
[PMID: 22533850]
|
HeLa
|
EC50 |
32.7 μM
Compound: 3TC, Lamivudine
|
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
|
[PMID: 22352809]
|
Hepatocyte
|
EC50 |
0.05 μg/mL
Compound: 3-TC, Lamivudine
|
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days
|
[PMID: 20869253]
|
HepG2
|
IC50 |
|
Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay
Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay
|
[PMID: 17488817]
|
HepG2
|
CC50 |
|
Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
|
[PMID: 25849312]
|
HepG2
|
CC50 |
|
Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
|
[PMID: 25849312]
|
HepG2
|
IC50 |
|
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
|
[PMID: 28595015]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
|
[PMID: 28595015]
|
HepG2
|
IC50 |
|
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
|
[PMID: 30653317]
|
HepG2
|
IC50 |
|
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
|
[PMID: 30653317]
|
HepG2
|
CC50 |
|
Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28688280]
|
HepG2
|
CC50 |
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28094179]
|
HepG2
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915]
|
HepG2
|
EC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting
Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting
|
[PMID: 21333535]
|
HepG2
|
CC50 |
|
Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay
Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay
|
[PMID: 21333535]
|
HepG2
|
CC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay
|
[PMID: 35776695]
|
HepG2
|
EC50 |
0.038 μM
Compound: Lamivudine (3TC)
|
Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
|
10.1016/S0960-894X(97)00422-8
|
HepG2
|
EC50 |
0.4 μM
Compound: 3TC (2'-deoxy-3'thiacytidine)
|
In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV
In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV
|
[PMID: 12852943]
|
HepG2
|
CC50 |
|
Cytotoxicity against HBV transfected human HepG2 cells by MTT assay
Cytotoxicity against HBV transfected human HepG2 cells by MTT assay
|
[PMID: 17488817]
|
HepG2
|
CC50 |
1200 μM
Compound: 3TC, lamivudine
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 17404006]
|
HepG2
|
IC50 |
1792 μM
Compound: Lamivudine (3TC)
|
Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
|
10.1016/S0960-894X(97)00422-8
|
HepG2 2.2.15
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay
|
[PMID: 28494252]
|
HepG2 2.2.15
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay
|
[PMID: 27484509]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay
Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay
|
[PMID: 35123297]
|
HepG2 2.2.15
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay
|
[PMID: 32712535]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 33285406]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 32791397]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 31091479]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288943]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay
Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay
|
[PMID: 17488817]
|
HepG2 2.2.15
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
|
[PMID: 21930377]
|
HepG2 2.2.15
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
|
[PMID: 21930377]
|
HepG2 2.2.15
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb
|
[PMID: 21930377]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
[PMID: 20117930]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
[PMID: 20117930]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
[PMID: 20117930]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA
|
[PMID: 23369536]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay
|
[PMID: 23369536]
|
HepG2 2.2.15
|
CC50 |
> 1000 μM
Compound: lamivudine
|
Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay
Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay
|
[PMID: 17499889]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay
|
[PMID: 29174810]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay
|
[PMID: 35754374]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay
|
[PMID: 27748590]
|
HepG2 2.2.15
|
CC50 |
> 2 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay
|
[PMID: 28682067]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 36228413]
|
HepG2 2.2.15
|
IC50 |
|
Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs
Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs
|
[PMID: 19072694]
|
HepG2 2.2.15
|
EC50 |
> 500 μM
Compound: Lamivudine
|
Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h
Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h
|
[PMID: 21930377]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis
|
[PMID: 32421339]
|
HepG2 2.2.15
|
EC50 |
0.02 μM
Compound: lamivudine
|
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
|
[PMID: 17004726]
|
HepG2 2.2.15
|
EC50 |
0.02 μM
Compound: lamivudine
|
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
|
[PMID: 15615545]
|
HepG2 2.2.15
|
IC50 |
0.039 μM
Compound: lamivudine
|
Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay
Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay
|
[PMID: 26260336]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs
|
[PMID: 19072694]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting
|
[PMID: 21333535]
|
HepG2 2.2.15
|
EC50 |
0.1 μM
Compound: 3TC, lamivudine
|
Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR
Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR
|
[PMID: 17404006]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs
|
[PMID: 19072694]
|
HepG2 2.2.15
|
IC50 |
0.16 μM
Compound: Lamivudine
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis
|
[PMID: 20639110]
|
HepG2 2.2.15
|
EC50 |
0.2 μg/mL
Compound: 3-TC, Lamivudine
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days
|
[PMID: 20869253]
|
HepG2 2.2.15
|
EC50 |
0.2 μM
Compound: Lamivudine
|
Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method
Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method
|
[PMID: 21930377]
|
HepG2 2.2.15
|
EC50 |
0.2 μM
Compound: Lamivudine
|
Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth
Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth
|
[PMID: 21930377]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
[PMID: 20117930]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
[PMID: 20117930]
|
HepG2 2.2.15
|
IC50 |
0.33 μM
Compound: lamivudine
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis
|
[PMID: 21524588]
|
HepG2 2.2.15
|
EC50 |
1.5 μM
Compound: Lamivudine
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
|
[PMID: 21930377]
|
HepG2 2.2.15
|
CC50 |
1020 μM
Compound: Lamivudine
|
Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay
Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay
|
[PMID: 28082068]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA
Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA
|
[PMID: 18396905]
|
HepG2 2.2.15
|
CC50 |
1174 μM
Compound: lamivudine
|
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
|
[PMID: 21524588]
|
HepG2 2.2.15
|
IC50 |
14.8 μg/mL
Compound: Lamivudine
|
Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay
Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay
|
[PMID: 20149495]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA
|
[PMID: 23434030]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA
|
[PMID: 23434030]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay
|
[PMID: 35754374]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay
Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay
|
[PMID: 21333535]
|
HepG2 2.2.15
|
CC50 |
2183.1 μM
Compound: lamivudine
|
Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining
Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining
|
[PMID: 19457674]
|
HepG2 2.2.15
|
CC50 |
2183.1 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method
Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method
|
[PMID: 21074429]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA
|
[PMID: 25847765]
|
HepG2 2.2.15
|
IC50 |
240 μM
Compound: Lamivudine
|
Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis
Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis
|
[PMID: 21074429]
|
HepG2 2.2.15
|
CC50 |
2400 μM
Compound: lamivudine
|
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
|
[PMID: 21401115]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA
Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA
|
[PMID: 18396905]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA
|
[PMID: 21823575]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA
|
[PMID: 25847765]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA
|
[PMID: 21145140]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA
|
[PMID: 21145140]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells by MTT assay
Cytotoxicity against human HepG2.2.15 cells by MTT assay
|
[PMID: 18396905]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA
|
[PMID: 21823575]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay
Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay
|
[PMID: 21823575]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay
|
[PMID: 23434030]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA
|
[PMID: 21183354]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA
|
[PMID: 23369536]
|
HepG2 2.2.15
|
IC50 |
49.13 μg/mL
Compound: 3TC
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA
|
[PMID: 25600408]
|
HepG2 2.2.15
|
CC50 |
5 μM
Compound: Lamivudine
|
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
|
[PMID: 20639110]
|
HepG2 2.2.15
|
EC50 |
|
Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
[PMID: 20117930]
|
HepG2 2.2.15
|
CC50 |
|
Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay
|
[PMID: 25847765]
|
HepG2 2.2.15
|
IC50 |
58 μM
Compound: lamivudine
|
Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA
Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA
|
[PMID: 21401115]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis
|
[PMID: 25847765]
|
HepG2 2.2.15
|
IC50 |
|
Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis
Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis
|
[PMID: 25461891]
|
HepG2 2.2.15
|
IC50 |
82.42 μM
Compound: Lamivudine
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA
|
[PMID: 21872478]
|
HepG2 2.2.15
|
IC50 |
82.42 μM
Compound: Lamivudine
|
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization
|
[PMID: 19307124]
|
HepG2 2.2.15
|
IC50 |
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis
|
[PMID: 23434030]
|
HL-60
|
CC50 |
1400 μM
Compound: 3TC, lamivudine
|
Cytotoxicity against human HL60 cells after 3 days by MTT assay
Cytotoxicity against human HL60 cells after 3 days by MTT assay
|
[PMID: 17404006]
|
Huh-7
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
[PMID: 19398648]
|
Huh-7
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
[PMID: 19398648]
|
Huh-7
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
[PMID: 19398648]
|
Huh-7
|
EC50 |
|
Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
[PMID: 17438047]
|
Huh-7
|
EC50 |
|
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
[PMID: 17438047]
|
Huh-7
|
CC50 |
|
Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay
Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay
|
[PMID: 21333535]
|
Huh-7
|
EC50 |
|
Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting
Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting
|
[PMID: 21333535]
|
Huh-7
|
EC50 |
0.2 μM
Compound: Lamivudine
|
Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
[PMID: 19398648]
|
Huh-7
|
EC50 |
|
Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
0.3 μM
Compound: Lamivudine
|
Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
[PMID: 19398648]
|
Huh-7
|
EC50 |
|
Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
[PMID: 17438047]
|
Huh-7
|
EC50 |
|
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
[PMID: 17438047]
|
Huh-7
|
EC50 |
|
Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
|
Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
Huh-7
|
EC50 |
16 μM
Compound: Lamivudine
|
Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
[PMID: 19398648]
|
Huh-7
|
EC50 |
|
Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
[PMID: 19072694]
|
L1210
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
|
[PMID: 24177359]
|
L1210
|
IC50 |
> 250 μM
Compound: 5, 3TC
|
Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
|
[PMID: 24177359]
|
MOLT-3
|
CC50 |
|
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
|
[PMID: 21334901]
|
MOLT-4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
0.8 μM
Compound: Lamivudine
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
|
[PMID: 21115794]
|
MT2
|
EC50 |
0.8 μM
Compound: Lamivudine
|
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
|
[PMID: 21115794]
|
MT2
|
EC50 |
0.8 μM
Compound: Lamivudine
|
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
|
[PMID: 21115794]
|
MT2
|
EC50 |
0.8 μM
Compound: Lamivudine
|
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi
|
[PMID: 21115794]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 34583311]
|
MT4
|
CC50 |
|
Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay
Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay
|
[PMID: 30265808]
|
MT4
|
CC50 |
> 7.5 μM
Compound: Lamivudine
|
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
|
[PMID: 31767136]
|
MT4
|
CC50 |
> 87 μM
Compound: lamivudine
|
Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay
|
[PMID: 25946116]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
|
[PMID: 25707013]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
|
[PMID: 25626145]
|
MT4
|
CC50 |
> 87 μM
Compound: lamivudine
|
Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay
|
[PMID: 24926807]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 24119448]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 32977301]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 30721060]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 28659246]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
|
[PMID: 27748590]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 27267005]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 24794751]
|
MT4
|
CC50 |
> 87.24 μM
Compound: 3 TC
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 31434039]
|
MT4
|
CC50 |
> 87.24 μM
Compound: 3 TC
|
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
|
[PMID: 25240095]
|
MT4
|
CC50 |
> 87.24 μM
Compound: Lamivudine
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 24952305]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35754374]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33279288]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days MTT assay
Cytotoxicity against human MT4 cells after 5 days MTT assay
|
[PMID: 25537532]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
|
[PMID: 35780636]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 30606670]
|
MT4
|
CC50 |
|
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 27541578]
|
MT4
|
CC50 |
|
Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 34890994]
|
MT4
|
IC50 |
|
Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells
Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells
|
[PMID: 8035429]
|
MT4
|
IC50 |
0.58 μg/mL
Compound: Lamivudine
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
|
[PMID: 27105027]
|
MT4
|
EC50 |
0.89 μM
Compound: Lamivudine
|
Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
|
[PMID: 25682562]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
|
[PMID: 24119448]
|
MT4
|
IC50 |
15.5 μM
Compound: lamivudine
|
Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
|
[PMID: 24926807]
|
MT4
|
EC50 |
15.5 μM
Compound: lamivudine
|
Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
|
[PMID: 25946116]
|
MT4
|
IC50 |
15.53 μM
Compound: Lamivudine
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 24952305]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25707013]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 27748590]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
|
[PMID: 25240095]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25537532]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
|
[PMID: 24794751]
|
MT4
|
CC50 |
20 μg/mL
Compound: Lamivudine
|
Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay
Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay
|
[PMID: 27105027]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25626145]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 27267005]
|
MT4
|
EC50 |
3.56 μM
Compound: Lamivudine
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
|
[PMID: 25682562]
|
MT4
|
IC50 |
3.89 μM
Compound: Lamivudine
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 24952305]
|
MT4
|
IC50 |
3.9 μM
Compound: lamivudine
|
Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
|
[PMID: 24926807]
|
MT4
|
EC50 |
3.9 μM
Compound: lamivudine
|
Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
|
[PMID: 25946116]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
|
[PMID: 24119448]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
|
[PMID: 24794751]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25537532]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 27748590]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
|
[PMID: 25240095]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578]
|
PBMC
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915]
|
PBMC
|
IC50 |
> 100 μM
Compound: 3TC, Epivir
|
Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
|
[PMID: 21700368]
|
PBMC
|
CC50 |
|
Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28688280]
|
PBMC
|
CC50 |
|
Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28094179]
|
PBMC
|
CC50 |
> 13097 nM
Compound: 1, lamivudine, 3TC
|
Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days
Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days
|
[PMID: 22533850]
|
PBMC
|
EC50 |
|
Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
[PMID: 18316521]
|
PBMC
|
EC50 |
|
Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
[PMID: 18316521]
|
PBMC
|
EC50 |
|
Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
[PMID: 18316521]
|
PBMC
|
EC50 |
|
Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
[PMID: 18316521]
|
PBMC
|
CC50 |
52.97 μg/mL
Compound: 3TC
|
Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay
Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay
|
[PMID: 21334901]
|
Vero
|
CC50 |
> 100 μg/mL
Compound: 3-TC(Lamivudine)
|
Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay
Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay
|
[PMID: 11985471]
|
Vero
|
CC50 |
> 100 μg/mL
Compound: 1a (Lamivudine)
|
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay
|
[PMID: 11677126]
|
Vero
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33421915]
|
Vero
|
IC50 |
> 100 μM
Compound: 3TC, Epivir
|
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
|
[PMID: 21700368]
|
Vero
|
CC50 |
|
Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28688280]
|
Vero
|
CC50 |
|
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
|
[PMID: 28094179]
|
WI-38
|
CC50 |
> 100 μM
Compound: Lamivudine
|
Cytotoxicity against human WI38 cells by neutral red assay
Cytotoxicity against human WI38 cells by neutral red assay
|
[PMID: 18285481]
|
WI-38
|
EC50 |
> 100 μM
Compound: Lamivudine
|
Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
|
[PMID: 18285481]
|